|
1
|
Arnold M, Park JY, Camargo MC, Lunet N,
Forman D and Soerjomataram I: Is gastric cancer becoming a rare
disease? A global assessment of predicted incidence trends to 2035.
Gut. 69:823–829. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koppe MJ, Boerman OC, Oyen WJ and
Bleichrodt RP: Peritoneal carcinomatosis of colorectal origin:
Incidence and current treatment strategies. Ann Surg. 243:212–222.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugarbaker PH, Landy D and Pascal R:
Intraperitoneal chemotherapy for peritoneal carcinomatosis from
colonic or appendiceal cystadenocarcinoma: Rationale and results of
treatment. Prog Clin Biol Res. 354B:141–170. 1990.PubMed/NCBI
|
|
4
|
Khomyakov V, Ryabov A, Ivanov A, Bolotina
L, Utkina A, Volchenko N and Kaprin A: Bidirectional chemotherapy
in gastric cancer with peritoneal metastasis combining intravenous
XELOX with intraperitoneal chemotherapy with low-dose cisplatin and
Doxorubicin administered as a pressurized aerosol: An open-label,
Phase-2 study (PIPAC-GA2). Pleura Peritoneum. 1:159–166. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tempfer CB, Rezniczek GA, Ende P, Solass W
and Reymond MA: Pressurized Intraperitoneal Aerosol Chemotherapy
with Cisplatin and Doxorubicin in Women with Peritoneal
Carcinomatosis: A Cohort Study. Anticancer Res. 35:6723–6729.
2015.PubMed/NCBI
|
|
6
|
Demtroder C, Solass W, Zieren J, Strumberg
D, Giger-Pabst U and Reymond MA: Pressurized intraperitoneal
aerosol chemotherapy with oxaliplatin in colorectal peritoneal
metastasis. Colorectal Dis. 18:364–371. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alyami M, Gagniere J, Sgarbura O,
Cabelguenne D, Villeneuve L, Pezet D, Quenet F, Glehen O, Bakrin N
and Passot G: Multicentric initial experience with the use of the
pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the
management of unresectable peritoneal carcinomatosis. Eur J Surg
Oncol. 43:2178–2183. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khosrawipour T, Khosrawipour V and
Giger-Pabst U: Pressurized intra peritoneal aerosol chemotherapy in
patients suffering from peritoneal carcinomatosis of pancreatic
adenocarcinoma. PLoS One. 12:e01867092017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Falkenstein TA, Gotze TO, Ouaissi M,
Tempfer CB, Giger-Pabst U and Demtroder C: First clinical data of
pressurized intraperitoneal aerosol chemotherapy (PIPAC) as salvage
therapy for peritoneal metastatic biliary tract cancer. Anticancer
Res. 38:373–378. 2018.PubMed/NCBI
|
|
10
|
Horvath P, Beckert S, Struller F,
Konigsrainer A and Reymond MA: Pressurized intraperitoneal aerosol
chemotherapy (PIPAC) for peritoneal metastases of pancreas and
biliary tract cancer. Clin Exp Metastasis. 35:635–640. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hubner M, Alyami M, Villeneuve L,
Cortes-Guiral D, Nowacki M, So J and Sgarbura O; ISSPP PIPAC study
groupL, : Consensus guidelines for pressurized intraperitoneal
aerosol chemotherapy: Technical aspects and treatment protocols.
Eur J Surg Oncol. 48:789–794. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hubner M, Teixeira Farinha H, Grass F,
Wolfer A, Mathevet P, Hahnloser D and Demartines N: Feasibility and
safety of pressurized intraperitoneal aerosol chemotherapy for
peritoneal carcinomatosis: A retrospective cohort study.
Gastroenterol Res Pract. 2017:68527492017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reymond MA, Hu B, Garcia A, Reck T,
Köckerling F, Hess J and Morel P: Feasibility of therapeutic
pneumoperitoneum in a large animal model using a microvaporisator.
Surg Endosc. 14:51–55. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Solaß W, Hetzel A, Nadiradze G, Sagynaliev
E and Reymond MA: Description of a novel approach for
intraperitoneal drug delivery and the related device. Surg Endosc.
26:1849–1855. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Solass W, Kerb R, Mürdter T, Giger-Pabst
U, Strumberg D, Tempfer C, Zieren J, Schwab M and Reymond MA:
Intraperitoneal chemotherapy of peritoneal carcinomatosis using
pressurized aerosol as an alternative to liquid solution: First
evidence for efficacy. Ann Surg Oncol. 21:553–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Solass W, Herbette A, Schwarz T, Hetzel A,
Sun JS, Dutreix M and Reymond MA: Therapeutic approach of human
peritoneal carcinomatosis with Dbait in combination with
capnoperitoneum: Proof of concept. Surg Endosc. 26:847–852. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Giorgio A, Macri A, Ferracci F, Robella
M, Visaloco M, De Manzoni G, Sammartino P, Sommariva A, Biacchi D,
Roviello F, et al: 10 Years of pressurized intraperitoneal aerosol
chemotherapy (PIPAC): A systematic review and meta-analysis.
Cancers (Basel). 15:11252023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Daniel SK, Sun BJ and Lee B: PIPAC for
Gastrointestinal Malignancies. J Clin Med. 12:67992023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grass F, Vuagniaux A, Teixeira-Farinha H,
Lehmann K, Demartines N and Hubner M: Systematic review of
pressurized intraperitoneal aerosol chemotherapy for the treatment
of advanced peritoneal carcinomatosis. Br J Surg. 104:669–678.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tempfer CB, Giger-Pabst U, Seebacher V,
Petersen M, Dogan A and Rezniczek GA: A phase I, single-arm,
open-label, dose escalation study of intraperitoneal cisplatin and
doxorubicin in patients with recurrent ovarian cancer and
peritoneal carcinomatosis. Gynecol Oncol. 150:23–30. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Odendahl K, Solass W, Demtroder C,
Giger-Pabst U, Zieren J, Tempfer C and Reymond MA: Quality of life
of patients with end-stage peritoneal metastasis treated with
pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J
Surg Oncol. 41:1379–1385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nadiradze G, Giger-Pabst U, Zieren J,
Strumberg D, Solass W and Reymond MA: Pressurized intraperitoneal
aerosol chemotherapy (PIPAC) with low-dose cisplatin and
doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg.
20:367–373. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gockel I, Jansen-Winkeln B, Haase L, Rhode
P, Mehdorn M, Niebisch S, Moulla Y, Lyros O, Lordick F, Schierle K,
et al: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in
gastric cancer patients with peritoneal metastasis (PM): Results of
a single-center experience and register study. J Gastric Cancer.
18:379–391. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sgarbura O, Hubner M, Alyami M, Eveno C,
Gagniere J, Pache B, Pocard M, Bakrin N and Quénet F: Oxaliplatin
use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is
safe and effective: A multicenter study. Eur J Surg Oncol.
45:2386–2391. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alyami M, Bonnot PE, Mercier F, Laplace N,
Villeneuve L, Passot G, Bakrin N, Kepenekian V and Glehen O:
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for
unresectable peritoneal metastasis from gastric cancer. Eur J Surg
Oncol. 47:123–127. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sugarbaker PH and Jablonski KA: Prognostic
features of 51 colorectal and 130 appendiceal cancer patients with
peritoneal carcinomatosis treated by cytoreductive surgery and
intraperitoneal chemotherapy. Ann Surg. 221:124–132. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Giger-Pabst U, Demtroder C, Falkenstein
TA, Ouaissi M, Götze TO, Rezniczek GA and Tempfer CB: Pressurized
intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of
malignant mesothelioma. BMC Cancer. 18:4422018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harmon RL and Sugarbaker PH: Prognostic
indicators in peritoneal carcinomatosis from gastrointestinal
cancer. Int Semin Surg Oncol. 2:32005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Solass W, Sempoux C, Detlefsen S, Carr NJ
and Bibeau F: Peritoneal sampling and histological assessment of
therapeutic response in peritoneal metastasis: Proposal of the
peritoneal regression grading score (PRGS). Pleura Peritoneum.
1:99–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hubner M, Somashekhar SP, Teixeira Farinha
H, Abba J, Rao RG, Alyami M and Willaert W: Treatment response
after pressurized intra peritoneal aerosol chemotherapy (PIPAC) for
peritoneal metastases of colorectal originf. Ann Surg Open.
3:e2032022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kurtz F, Struller F, Horvath P, Solass W,
Bosmuller H, Königsrainer A and Reymond MA: Feasibility, safety,
and efficacy of pressurized intraperitoneal aerosol chemotherapy
(PIPAC) for peritoneal metastasis: A registry study. Gastroenterol
Res Pract. 2018:27439852018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mandard AM, Dalibard F, Mandard JC, Marnay
J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G,
et al: Pathologic assessment of tumor regression after preoperative
chemoradiotherapy of esophageal carcinoma. Clinicopathologic
correlations. Cancer. 73:2680–2686. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Becker K, Mueller JD, Schulmacher C, Ott
K, Fink U, Busch R, Böttcher K, Siewert JR and Höfler H:
Histomorphology and grading of regression in gastric carcinoma
treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baldus SE, Monig SP, Schroder W, Metzger
R, Lang S, Zirbes TK, Thiele J, Müller RP, Dienes HP, Hölscher AH
and Schneider PM: Regression of oesophageal carcinomas after
neoadjuvant radiochemotherapy: Criteria of the histopathological
evaluation. Pathologe. 25:421–427, (In German). View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dworak O, Keilholz L and Hoffmann A:
Pathological features of rectal cancer after preoperative
radiochemotherapy. Int J Colorectal Dis. 12:19–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rubbia-Brandt L, Giostra E, Brezault C,
Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE,
Soubrane O, et al: Importance of histological tumor response
assessment in predicting the outcome in patients with colorectal
liver metastases treated with neo-adjuvant chemotherapy followed by
liver surgery. Ann Oncol. 18:299–304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blazer DG III, Kishi Y, Maru DM, Kopetz S,
Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, et al:
Pathologic response to preoperative chemotherapy: A new outcome end
point after resection of hepatic colorectal metastases. J Clin
Oncol. 26:5344–5351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Solass W, Sempoux C, Carr NJ, Bibeau F,
Neureiter D, Jäger T, Di Caterino T, Brunel C, Klieser E, Fristrup
CW, et al: Reproducibility of the peritoneal regression grading
score for assessment of response to therapy in peritoneal
metastasis. Histopathology. 74:1014–1024. 2019. View Article : Google Scholar : PubMed/NCBI
|
